Company profile: Vaxxinity
1.1 - Company Overview
Company description
- Provider of synthetic peptide vaccine technologies and Active Immunotherapy Medicines (AIMs) that stimulate antibody production to address chronic and infectious diseases, including UB-311 for mild Alzheimerβs (targets amyloid beta), UB-312 for Parkinsonβs (targets alpha-synuclein), VXX-401 anti-PCSK9 to reduce LDL-C for heart disease, and UB-612, a multitope protein-peptide vaccine against SARS-CoV-2 variants like Omicron.
Products and services
- Active Immunotherapy Medicines (AIMs): An immunotherapeutic platform that stimulates the body's immune system to produce antibodies for treating chronic diseases, activating endogenous immunity to generate therapeutic antibody responses
- UB-311: A synthetic peptide-based vaccine targeting amyloid Ξ² to treat mild Alzheimer's disease, inducing antibody responses specific to amyloid Ξ² to support therapeutic intervention
- UB-612: A multitope protein-peptide vaccine engineered to elicit immune responses against SARS-CoV-2, including variants like Omicron, leveraging its multitope design to stimulate antiviral antibody production
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Vaxxinity
Adapt Pharma
HQ: United States
Website
- Description: Provider of therapeutic treatments for patients with special medical conditions, including NARCAN (naloxone hydrochloride) Nasal Spray, an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Adapt Pharma company profile β
Supernus Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products for central nervous system diseases, developing and commercializing therapies including Qelbree for ADHD; Trokendi XR for epilepsy and migraine prevention; and Oxtellar XR for epilepsy, with pipeline candidates SPN-830 for hypomobility in Parkinsonβs disease, SPN-820/821 for treatment-resistant depression, and SPN-817 for severe epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Supernus Pharmaceuticals company profile β
Contineum Therapeutics
HQ: United States
Website
- Description: Provider of novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791, an LPA1R antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis (RRMS) and depression; and LPA1R DC, a peripherally restricted LPA1R antagonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Contineum Therapeutics company profile β
Trevena
HQ: United States
Website
- Description: Provider of an approved intravenous opioid analgesic (OLINVYK) for the management of acute pain in adults when alternative treatments are inadequate, and developer of GPCR-biased ligands, including TRV045 (oral S1P receptor; diabetic neuropathic pain and epilepsy; Phase 1), TRV250 (delta receptor; acute migraine; Phase 1), and TRV734 (oral mu receptor; maintenance treatment of opioid use disorder; Phase 1).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Trevena company profile β
Adamas Pharma
HQ: United States
Website
- Description: Provider of controlled and extended-release combination therapeutics for infectious diseases and central nervous system disorders, including products for symptomatic treatment of dementia. Offerings include Qelbree for ADHD; Trokendi XR and Oxtellar XR for epilepsy and migraine prevention; and candidates SPN-830 (hypomobility in Parkinsonβs disease), SPN-820/821 (treatment-resistant depression), SPN-817 (severe epilepsy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Adamas Pharma company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Vaxxinity
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vaxxinity
2.2 - Growth funds investing in similar companies to Vaxxinity
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Vaxxinity
4.2 - Public trading comparable groups for Vaxxinity
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β